Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,556.00
Bid: 12,548.00
Ask: 12,550.00
Change: 6.00 (0.05%)
Spread: 2.00 (0.016%)
Open: 12,570.00
High: 12,704.00
Low: 12,472.00
Prev. Close: 12,550.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 2-India celebrates 1 billion COVID-19 vaccine doses with song and dance

Thu, 21st Oct 2021 06:21

* India reaches milestone after slow start in mid-January

* Huge disparity between partly and fully vaccinated people

* WHO, UNICEF congratulate India, urge it to resume COVAX
supplies
(Adds graphics, UNICEF comment)

By Krishna N. Das

NEW DELHI, Oct 21 (Reuters) - India celebrated the milestone
of administering 1 billion COVID-19 vaccine doses on Thursday,
with the government promoting the achievement in song and video
even as a recent drop in inoculations worries healthcare
providers.

After a slow beginning in the middle of January, India's
immunisation campaign has covered three-quarters of its 944
million adults with at least one dose but only 31% with two. The
government wants all adults to get vaccinated this year.

"India scripts history," Prime Minister Narendra Modi said
on Twitter. "We are witnessing the triumph of Indian science,
enterprise and collective spirit of (1.3 billion) Indians."

Modi marked the occasion by interacting with healthcare
workers and a security guard at a government hospital in New
Delhi. The health ministry announced musical and other
programmes across the country, and special illuminations of
national monuments including a colonial-era jail.

Nearly 90% of the vaccines administered in India have come
from the Serum Institute of India (SII), which produces a
licensed version of the AstraZeneca drug. SII has more
than tripled its capacity since April and can now produce 220
million vaccine doses a month.

SII has also slowly resumed exports for the first time since
April, when the government stopped all overseas sales to meet
domestic demand as infections rose dramatically.

The World Health Organization (WHO), which relies heavily on
India for supplies to its global vaccine-sharing platform COVAX,
congratulated the country for reaching the landmark.

"India's progress must be viewed in the context of the
country's commendable commitment and efforts to ensure that
these life-saving vaccines are accessible globally," said Poonam
Khetrapal Singh, regional director WHO South-East Asia.

COVAX partner UNICEF also congratulated India and said it
looked forward to "hearing details about the expected timeline
and volumes of supplies to be made" to the global facility.

Reuters has reported that India has delayed supplies of the
AstraZeneca vaccine to COVAX https://www.reuters.com/world/india/india-delays-covid-19-vaccine-supplies-who-backed-covax-sources-say-2021-10-19.
New Delhi has been annoyed by the WHO's repeated delay in
adding India's own Covaxin shot to the world body's
emergency-use listing https://twitter.com/DrTedros/status/1450574012027920402,
something both parties discussed this week as well as exports.

India has so far reported 34.1 million COVID-19 cases and
more than 452,000 deaths, most during a second wave of
infections of the Delta variant between April and May.

A "sizeable number https://www.reuters.com/article/health-coronavirus-india/many-indians-skipping-second-covid-shot-despite-record-vaccine-stocks-idUSL4N2RF2G3
" of people in India have not taken their second dose by the due
date despite adequate supplies, the health ministry said on
Tuesday, as new infections fell to their lowest since early
March.

Daily shots have averaged 5 million this month, a fifth of
September's peak, though states are sitting on record stocks of
more than 100 million as domestic output of the AstraZeneca
vaccine soars.

Despite the current low number of infections, ministry
officials have been urging people to get vaccinated fast,
especially as the ongoing festival season means family
gatherings and mass shopping, raising the risk of a new wave of
infections.

(Reporting by Krishna N. Das; Editing by Lincoln Feast and
Giles Elgood)

More News
26 Jun 2024 08:40

TOP NEWS: AstraZeneca's Tagrisso plus chemo gets approval in China

(Alliance News) - AstraZeneca PLC on Wednesday celebrated the approval of Tagrisso plus chemotherapy for a cancer form in China, a day after a similar approval in Japan.

Read more
25 Jun 2024 09:05

TOP NEWS: AstraZeneca details mixed findings from cancer drug trials

(Alliance News) - AstraZeneca PLC on Tuesday announced a mixed bag of results for two of its leading cancer drugs Imfinzi and Tagrisso.

Read more
25 Jun 2024 07:48

LONDON BRIEFING: Mixed bag for Astra drug; Landsec ups Bluewater stake

(Alliance News) - London's FTSE 100 is set to tread water on Tuesday, with a slump for US tech shares overnight keeping a lid on enthusiasm.

Read more
25 Jun 2024 07:17

AstraZeneca posts mixed results from recent Imfinzi trials

(Sharecast News) - AstraZeneca announced contrasting results from two phase three trials involving its immunotherapy drug 'Imfinzi', or durvalumab, on Tuesday.

Read more
24 Jun 2024 15:40

US Supreme Court gives pharma companies a chance to thwart terrorism-funding lawsuit

WASHINGTON, June 24 (Reuters) - The U.S. Supreme Court gave a boost on Monday to a challenge by 21 pharmaceutical and medical equipment companies led by AstraZeneca to a lawsuit accusing them of illegally helping to fund terrorism that killed or injured hundreds of American troops and civilians in Iraq.

Read more
24 Jun 2024 14:56

US Supreme Court gives pharma companies a chance to thwart terrorism-funding lawsuit

WASHINGTON, June 24 (Reuters) - The U.S. Supreme Court gave boost on Monday to a challenge by 21 pharmaceutical and medical equipment companies led by AstraZeneca to a lawsuit accusing them of illegally helping to fund terrorism that killed or injured hundreds of American troops and civilians in Iraq.

Read more
20 Jun 2024 10:56

TOP NEWS: AstraZeneca's Truqap gets OK from EU for breast cancer form

(Alliance News) - AstraZeneca PLC on Thursday said that the EU approved its prescription medicine Truqap, in combination with hormonal therapy Faslodex, for the treatment of a form of breast cancer.

Read more
18 Jun 2024 09:33

TOP NEWS: AstraZeneca disappointed by breast cancer drug trial results

(Alliance News) - AstraZeneca PLC on Tuesday said findings from a breast cancer drug trial showed that Truqap did not meet its primary endpoints.

Read more
18 Jun 2024 07:51

LONDON BRIEFING: Ashtead profit declines; Whitbread sales rise

(Alliance News) - London's FTSE 100 is called to open higher on Tuesday, taking confidence from a decent showing for US equities overnight, with inflation data and central bank decisions the key plot points as the week progresses.

Read more
18 Jun 2024 07:17

AstraZeneca trial fails to treat 'challenging' breast cancer

(Sharecast News) - AstraZeneca announced on Tuesday that the phase three 'CAPItello-290' trial for 'Truqap', or capivasertib, in combination with paclitaxel did not achieve its primary endpoints.

Read more
17 Jun 2024 09:09

TOP NEWS: Astra's Imfinzi plus chemo approved for cancer form in US

(Alliance News) - AstraZeneca PLC on Monday said it secured a new US approval for cancer treatment Imfinzi, also known as durvalumab, hailing an "important new option" for patients.

Read more
17 Jun 2024 07:48

LONDON BRIEFING: Astra gets US drug approval; Ascential trades in line

(Alliance News) - London's FTSE 100 is called to open solidly higher on Monday, recovering some poise after a tricky week, with eyes turning to the Bank of England.

Read more
17 Jun 2024 07:23

IN BRIEF: AstraZeneca gets positive cancer test results for Calquence

AstraZeneca PLC - Cambridge, England-based pharmaceutical maker - Reports promising test results for one of its cancer therapies. The Echo phase III trial shows that Calquence, when used in combination with bendamustine and rituximab, demonstrates a clinically meaningful improvement in progression-free survival in patients with untreated mantle cell lymphoma. Compared to standard-of-care chemoimmunotherapy, the combination with Calquence, whose generic name is acalabrutinib, shows a 27% reduced risk of disease progression or death. Mantle cell lymphoma is rare and typically aggressive form of non-Hodgkin lymphoma, Astra explains.

Read more
17 Jun 2024 07:15

AstraZeneca's Imfinzi gets US approval for endometrial cancer patients

(Sharecast News) - AstraZeneca said its Imfinzi cancer treatment had been approved in the US as treatment for adult patients with primary advanced or recurrent endometrial cancer.

Read more
12 Jun 2024 20:56

AstraZeneca's Farxiga approved to treat paediatric type-2 diabetes

(Alliance News) - AstraZeneca PLC on Wednesday said its Farxiga treatment has been approved in the US to treat some diabetes sufferers.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.